Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.33 |
| ▸ | CTSL | P07711 | 6/20 | 0.33 |
| ▸ | CTSK | P43235 | 6/20 | 0.32 |
| ▸ | MME | P08473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15064325 | 1.00 | CTSS (0.33) | CTSSCTSLCTSKMMELMNA | |
| SCHEMBL15064608 | 0.86 | CTSS (0.36) | CTSSCTSLCTSK | |
| SCHEMBL16908820 | 0.82 | CTSS (0.34) | CTSSCTSLCTSK | |
| SCHEMBL15086637 | 0.82 | CTSS (0.33) | CTSSCTSLCTSK | |
| SCHEMBL12069218 | 0.81 | CTSS (0.53) | CTSSCTSLCTSK | |
| SCHEMBL15086646 | 0.80 | CTSL (0.41) | CTSSCTSLCTSK | |
| SCHEMBL12070309 | 0.79 | GRIK1 (0.31) | LMNA | |
| SCHEMBL12069223 | 0.78 | TP53 (0.33) | CTSSCTSLCTSKMME | |
| SCHEMBL16408514 | 0.76 | CTSS (0.33) | CTSSCTSLCTSK | |
| SCHEMBL15086600 | 0.76 | CTSS (0.32) | CTSSCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025250-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD | 2015-01-22 | — | — | US | disclosed |
| US-8859505-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-10-14 | — | — | US | disclosed |
| EP-2752404-A1 | Cysteine protease inhibitors | Medivir UK Ltd (GB) | 2014-07-09 | — | — | EP | disclosed |
| US-20130172232-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025250-A1 | CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTRB1 | CTSS 2/4885CTSL 9/4885CTSK 13/4885 |
| US-20130172232-A1 | CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTRB1 | CTSS 2/4885CTSL 9/4885CTSK 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.